News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Balance sheet
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Denali Therapeutics (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the company's stock for approximately $71,625, reducing his position by 1% while still holding over 281,000 shares. Despite the company missing analysts' EPS estimates with a quarterly loss of $0.68 per share, revenue exceeded …
Sei Investments Co. has acquired 52,235 shares of Denali Therapeutics Inc. (NASDAQ:DNLI) valued at approximately $1.0 million, contributing to institutional investors' 92.92% ownership of the company. Despite reporting a quarterly loss of $0.68 per share, Denali's revenue exceeded expectations, and analysts maintain a "Moderate …
E. Ohman J or Asset Management AB recently acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI), purchasing 160,000 shares valued at approximately $4.1 million, giving them a 0.10% stake in the company. Institutional investors collectively own 92.92% of DNLI, with several other hedge …
Baillie Gifford reduced its stake in Denali Therapeutics Inc (DNLI) by 106,249 shares on June 30, 2026, lowering its total holdings to 11,960,230 shares. This transaction, representing a minor -0.88% change in the firm's portfolio, reflects a continued focus on long-term growth by the …
Denali Therapeutics has exceeded analyst expectations with its new Hunter syndrome therapy, Avlayah, reporting $3.6 million in revenue during its first quarter on the market, significantly surpassing the anticipated $1.3 million. The company has raised its third-quarter revenue guidance to $10-$12 million, driven by …
The Manufacturers Life Insurance Company significantly reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 31.9% in the first quarter, selling 58,796 shares and retaining 125,442 shares valued at approximately $2.4 million. Despite this, institutional investors collectively own 92.92% of the stock, and analysts …
This article analyzes Denali Therapeutics Inc. (NASDAQ: DNLI) using AI models, highlighting strong sentiment across all time horizons and an exceptional 41.9:1 risk-reward setup. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes …
Denali Therapeutics (DNLI) saw its shares rise 7.9% after reporting Q2 2026 results, which included the first full-quarter commercial revenue from its drug AVLAYAH. Despite a net loss of US$127.55 million, the company highlighted growing operational and financial platforms due to AVLAYAH's launch, expanded …
Analysts have issued a "Moderate Buy" consensus rating for Denali Therapeutics Inc. (NASDAQ:DNLI), with an average 12-month price target of $35.92, significantly above its current trading price. This comes despite the company reporting a quarterly loss of $0.68 per share, which missed consensus estimates, …
Wall Street Zen has upgraded Denali Therapeutics (NASDAQ:DNLI) from a "sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average price target of $35.92. Despite missing quarterly EPS estimates, Denali reported higher-than-forecast revenue, and institutional investors hold …
The average 12-month price target for Denali Therapeutics Inc. (DNLI) stock has been raised to $35.44 from $34.31 by 16 analysts, with forecasts ranging from $27 to $42 per share. This new target implies a potential upside of approximately 43% from its August 6 …
Denali Therapeutics (DNLI) reported a narrower Q2 2026 loss of 68 cents per share, surpassing the Zacks Consensus Estimate. The company's net product revenues reached $3.6 million, driven by the strong initial commercial sales of its newly FDA-approved drug, Avlayah, for Hunter Syndrome. Denali's …
Wedbush has increased its price target on Denali Therapeutics Inc. (DNLI) to $27 from $26, while maintaining an Outperform rating. This adjustment comes shortly after Denali Therapeutics reported its Q2 2026 earnings, posting a loss of $0.68 per share but exceeding revenue expectations with …
Denali Therapeutics reported strong financial results for Q2 2026, driven by the successful launch of AVLAYAH™, which generated $3.6 million in net product revenue. The company also announced the advancement of two Alzheimer’s disease programs into clinical development and received $195 million from the …
Denali Therapeutics Inc. reported second-quarter 2026 financial results, marking its first product revenue of $3.6M from the commercial launch of AVLAYAH, despite continuing to incur a net loss and negative EPS. The company highlighted AVLAYAH's accelerated FDA approval and initial U.S. sales, operational scale-up …
Denali Therapeutics reported a Q2 2026 revenue miss, posting $3.6 million against an expected $11.94 million, and a wider-than-forecast loss of $0.68 per share. Despite the miss, the stock rose in after-hours trading as investors focused on the early, encouraging commercial launch of AVLAYAH, …
Denali Therapeutics Inc. (DNLI) reported Q2 revenue of $3.6 million, significantly surpassing FactSet's estimated $2.2 million. The company is focused on developing biotherapeutics that cross the blood-brain barrier for treating neurological conditions and other diseases. Denali also anticipates Q3 revenue to range between $10.0 …
Denali Therapeutics reported a Q2 2026 net loss of $127.6 million and $3.6 million in net product revenue from its newly launched therapy, AVLAYAH, for Hunter syndrome. The company also announced the discontinuation of a Parkinson's disease program (BIIB122/DNL151) after its Phase 2b study …
Denali Therapeutics Inc. (DNLI) reported a Q2 loss of $0.68 per share, outperforming the Zacks Consensus Estimate of a $0.72 loss. The company also surpassed revenue estimates with $3.6 million, significantly higher than zero revenues a year ago. Despite outperforming the market year-to-date, Denali …
Baillie Gifford & Co has reported a 7.54% stake in Denali Therapeutics (DNLI) common stock, according to an amended Schedule 13G filing. The investment adviser beneficially owns 11,960,230 shares, holding sole voting power over 11,915,890 shares and sole dispositive power over all 11,960,230 shares …
This article analyzes Denali Therapeutics Inc. (NASDAQ: DNLI) using AI models to inform risk allocation. It highlights divergent sentiment across time horizons, indicating choppy conditions, and points out a significant 41.3:1 risk-reward setup. The analysis provides specific institutional trading strategies, including long, breakout, and …
Denali Therapeutics (NASDAQ: DNLI) has approximately 516 employees worldwide as of March 2026, marking a 14.9% growth since 2023. The company is actively hiring, with 38 job postings in 2026, though this represents a 40% decline from 2025. The workforce is primarily located in …
Denali Therapeutics announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). The sale generated gross proceeds of $95 million, which the company intends to use to support its pipeline and operations. This strategic move highlights Denali's efforts to …
Denali Therapeutics has sold its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds to a large pharmaceutical company. This voucher was granted after the FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026. The transaction officially closed on …
This article provides a detailed quarterly and annual cash flow statement for Denali Therapeutics Inc (DNLI), encompassing operating, investing, and financing activities. It presents key financial data, including net income, capital expenditures, and free cash flow over several fiscal quarters. The report also includes …
Search by ticker symbol or company name and select a result to open its chart.